[{"address1": "171 Oyster Point Boulevard", "address2": "Suite 500", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 825 6990", "website": "https://www.tenayatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 140, "companyOfficers": [{"maxAge": 1, "name": "Mr. Faraz  Ali M.B.A.", "age": 51, "title": "CEO, Interim Principal Financial Officer & Director", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 890059, "exercisedValue": 0, "unexercisedValue": 1142905}, {"maxAge": 1, "name": "Dr. Deepak  Srivastava M.D.", "age": 58, "title": "Scientific Founder, Chairman of Scientific Advisory Board & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 120500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Whittemore G. Tingley M.D., PH.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 645786, "exercisedValue": 0, "unexercisedValue": 192187}, {"maxAge": 1, "name": "Dr. Eric N. Olson Ph.D.", "title": "Scientific Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce R. Conklin", "title": "Scientific Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Saptarsi  Haldar M.D.", "title": "Scientific Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sheng  Ding Ph.D.", "title": "Scientific Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Benoit G. Bruneau Ph.D.", "title": "Scientific Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kee-Hong  Kim Ph.D.", "age": 58, "title": "Chief Technology Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Corral", "title": "Vice President of Investor Relationship & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.42, "open": 1.42, "dayLow": 1.325, "dayHigh": 1.485, "regularMarketPreviousClose": 1.42, "regularMarketOpen": 1.42, "regularMarketDayLow": 1.325, "regularMarketDayHigh": 1.485, "beta": 2.347, "forwardPE": -1.1613662, "volume": 1912113, "regularMarketVolume": 1912113, "averageVolume": 5038026, "averageVolume10days": 3044720, "averageDailyVolume10Day": 3044720, "bid": 1.43, "ask": 1.51, "bidSize": 500, "askSize": 300, "marketCap": 115661928, "fiftyTwoWeekLow": 0.987, "fiftyTwoWeekHigh": 7.01, "fiftyDayAverage": 2.3226, "twoHundredDayAverage": 3.058725, "currency": "USD", "enterpriseValue": 50730952, "floatShares": 54536988, "sharesOutstanding": 79220496, "sharesShort": 16690310, "sharesShortPriorMonth": 13122628, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.21069999, "heldPercentInsiders": 0.011729999, "heldPercentInstitutions": 0.73807, "shortRatio": 3.42, "shortPercentOfFloat": 0.3016, "impliedSharesOutstanding": 79220496, "bookValue": 1.421, "priceToBook": 1.0274454, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -117228000, "trailingEps": -1.44, "forwardEps": -1.24, "enterpriseToEbitda": -0.444, "52WeekChange": -0.5153583, "SandP52WeekChange": 0.24176979, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TNYA", "underlyingSymbol": "TNYA", "shortName": "Tenaya Therapeutics, Inc.", "longName": "Tenaya Therapeutics, Inc.", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "2244c099-c937-391d-9d2b-ae91c15b1439", "messageBoardId": "finmb_409125654", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.46, "targetHighPrice": 40.0, "targetLowPrice": 6.0, "targetMeanPrice": 18.5, "targetMedianPrice": 18.0, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 79469000, "totalCashPerShare": 1.003, "ebitda": -114182000, "totalDebt": 14538000, "quickRatio": 4.912, "currentRatio": 5.275, "debtToEquity": 12.911, "returnOnAssets": -0.45938998, "returnOnEquity": -0.84492993, "freeCashflow": -56520752, "operatingCashflow": -94037000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]